Alzamend Neuro, Inc. (NASDAQ:ALZN) Sees Significant Increase in Short Interest

Alzamend Neuro, Inc. (NASDAQ:ALZN) was the target of a significant increase in short interest during the month of January. As of January 31st, there was short interest totalling 78,800 shares, an increase of 6.1% from the January 15th total of 74,300 shares. Currently, 1.5% of the company’s shares are sold short. Based on an average daily volume of 130,700 shares, the short-interest ratio is presently 0.6 days.

Alzamend Neuro Stock Up 0.9 %

NASDAQ ALZN traded up $0.01 during trading on Friday, hitting $1.09. The stock had a trading volume of 40,875 shares, compared to its average volume of 69,567. Alzamend Neuro has a one year low of $1.05 and a one year high of $15.06. The stock has a 50 day simple moving average of $1.17 and a 200 day simple moving average of $1.66.

Alzamend Neuro (NASDAQ:ALZN) last posted its quarterly earnings results on Wednesday, December 11th. The company reported ($0.40) earnings per share for the quarter, beating the consensus estimate of ($2.38) by $1.98. Research analysts anticipate that Alzamend Neuro will post -1.68 earnings per share for the current year.

Analyst Upgrades and Downgrades

Separately, Ascendiant Capital Markets decreased their price objective on shares of Alzamend Neuro from $35.00 to $32.00 and set a “buy” rating for the company in a research note on Monday, December 16th.

Institutional Trading of Alzamend Neuro

A hedge fund recently bought a new stake in Alzamend Neuro stock. Geode Capital Management LLC purchased a new stake in shares of Alzamend Neuro, Inc. (NASDAQ:ALZN) in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 33,540 shares of the company’s stock, valued at approximately $39,000. Geode Capital Management LLC owned approximately 0.62% of Alzamend Neuro as of its most recent filing with the Securities & Exchange Commission. Institutional investors own 49.61% of the company’s stock.

About Alzamend Neuro

Alzamend Neuro, Inc, an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease.